

# THE MALABSORPTION BLOOD TEST TRIAL WILL HELP DETERMINE THE BENEFITS OF PANCREATIC ENZYME REPLACEMENT THERAPY IN PATIENTS WITH MILD TO MODERATE EXOCRINE PANCREATIC INSUFFICIENCY.

NCT07418593

---

Status	RECRUITING
Phase	Phase 4
Sponsor	Anna Evans Phillips
Enrollment	80 participants

## Key Eligibility Criteria

---

### Inclusion (3)

- e 18 years of age
- RAP (e 2 documented lifetime attacks with e 2 of 3 acute pancreatitis criteria) OR Chronic pancreatitis (Cambridge I or II with chronic abdominal pain OR Cambridge III or IV criteria)
- Fecal elastase e 50 within the preceding 12 months

### Exclusion (9)

- Allergy/Intolerance to PERT/MBT
- Taking medications that alter fat absorption (e.g. orlistat, Ursodeoxycholic acid, etc.)
- Taking GLP-1 Receptor Agonist therapy
- Fecal elastase  $\lt 50$  within preceding 12 months OR pre-existing diagnosis of severe Exocrine Pancreatic Insufficiency
- Receiving Pancreatic Enzyme Replacement Therapy for  $\gt 5$  days within the preceding 90 days
- ... and 4 more (see full listing online)

## Locations (2 total)

---

Johns Hopkins Medicine, Baltimore, Maryland, United States  
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States